Barry Ticho - 17 Feb 2026 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Reporting relationship: CHIEF MEDICAL OFFICER
Issuer ticker: STOK
Reported as of: 17 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Feb 2026, 16:25:56 UTC
Prior SEC filing: 05 Dec 2025
Next SEC filing: 17 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Allan, Attorney-in-Fact

Key filing fact

Barry Ticho filed Form 4 for Stoke Therapeutics, Inc. (STOK) on 19 Feb 2026.

Key facts

This page summarizes Barry Ticho's Form 4 filing for Stoke Therapeutics, Inc. (STOK).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 19 Feb 2026, 16:25.

Change

Previous filing in this sequence was filed on 05 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001780088 Primary reporting owner

Ticho Barry

Relationship: CHIEF MEDICAL OFFICER
Address: C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD
Signature: /s/ Jonathan Allan, Attorney-in-Fact
Signature date: 19 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STOK transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +60,000
Change %
Price: $0.000000
Shares after: 60,000
Date: 17 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $31.09
Footnotes: F1

STOK transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +40,000
Change %
Price: $0.000000
Shares after: 40,000
Date: 17 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

Footnote F2

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.

Footnote F3

The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.